Clinical evaluation of piribedil combined with idebenone on treatment of patients with Parkinson's disease
Wu Kejun
Wang Wan
Lyu Rilang
Chen Hua
Wang Mingjia
Hao Yingzi
An Yanru
Guo Qian
Abstract：Objective To observe the clinical effect of piribedil sustained-release tablets combined with idebenone on treatment of patients with Parkinson's disease(PD).Methods A total of 180 patients with PD who were treated in the No.215 Hospital of Shaanxi Nuclear Industry from May 2021 to May 2023 were prospectively recruited as the research subjects and randomly divided into the control group with 90 cases and the combination group with 90 cases according to the order of the admission using a random number table method.The control group was treated with piribedil sustained-release tablets and the combination group was added with idebenone.The oxidative stress injury indicators(superoxide dismutase(SOD),malondialdehyde(MDA),glutathione peroxi-dase(GSH-Px)),brain monoamine neurotransmitters(5-hydroxytryptamine(5-HT),dopamine(DA),norepinephrine(NE)),motor and non-motor symptoms(Unified Parkinson's Disease Rating Scale-Ⅲ(UPDRS-Ⅲ),Mini-Mental State Examination(MMSE)),clinical efficacy and adverse reactions were observed and compared between the two groups.Results The SOD and GSH-Px levels of the two groups were higher after the treatment for 3 months than before the treatment;the levels of the above indexes of the combination group were respectively(124.34±26.33)kU·L-1 and(107.69±15.36)U·μg-1,higher than(109.34±23.11)kU·L-1 and(90.36±14.21)U·μg-1 of the control group(t=4.061,7.856,both P<0.05);after 3 months of treatment,the MDA level of the two groups was decreased and the MDA level of the combination group was(15.68±3.67)mmol·L-1,lower than(21.39±4.29)mmol·L-1 of the control group(t=9.595,P<0.05).After 3 months of treatment,the levels of 5-HT,DA and NE of the two groups were increased compared with before treatment;the levels of the above indexes of the combination group were respectively(26.48±3.54)ng·mL-1,(8.06±1.35)ng·mL-1 and(15.04±1.57)ng·mL-1,higher than(22.34±4.35)ng·mL-1,(6.64±1.03)ng·mL-1 and(13.15±1.28)ng·mL-1 of the control group(t=7.002,7.933,8.851,all P<0.05).After 3 months of treatment,MMSE score in the two groups rose and the score of(22.95±3.08)points in the combination group was higher than(18.99±2.46)points in the control group(t=9.530,P<0.05).After 3 months of treatment,the UPDRS-Ⅲ score of the two groups was reduced compared with before treatment,and the UPDRS-Ⅲ score of the combination group was(20.46±5.34)points,lower than(25.33±6.28)points of the control group(t=5.604,P<0.05).The total effective rate was 94.44%(85/90)in the combination group,higher than 84.44%(76/90)in the control group(χ2=4.766,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The com-bination of idebenone and piribedil sustained-release tablets for PD patients is helpful to improve the oxidative stress indicators,brain monoamine neurotransmitters and motor and non-motor symptoms scores of patients,with efficacy and safety high.
Keywords：Parkinson's diseaseIdebenonePiribedilOxidative stress injuryMonoamine neurotransmitters
Publication Date：2025-08-25
Online Publishing Date：2025-09-01(First online date of this platform, not the publication date of the document)
Pages：4( 761-764 )